Results 161 to 170 of about 22,784 (283)

New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1247-1257, February 2026.
Abstract Aims Cancer diagnosis may increase the risk of developing prediabetes/diabetes and subsequently worsen survival in cancer patients. However, it is unclear whether this association is influenced by the timing of hyperglycemia onset or the use of antihyperglycemic medications.
Maci Winn, Svenja Pauleck, Stephanie Richardson, Richard Viskochil, Prasoona Karra, Howard Colman, Jennifer A. Doherty, Yizhe Xu, Siwen Hu‐Lieskovan, Michelle Litchman, Mary C. Playdon, Sheetal Hardikar   +11 more
wiley   +1 more source

DPP4 in diabetes [PDF]

, 2015
Diana Röhrborn
core   +1 more source

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors

, 2012
A. Nitta, H. Fujii, Satoshi Sakami, Mikiya Satoh, Junko Nakaki, Shiho Satoh, Hiroki Kumagai, Hideki Kawai   +7 more
openalex   +1 more source

Use of dipeptidyl peptidase IV inhibitor in the comprehensive management of type 2 diabetes mellitus in Chinese population [PDF]

, 2018
Juming Lu
openalex   +1 more source

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT‐J trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1278-1287, February 2026.
Abstract Aims This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. Materials and Methods This was a prespecified subgroup analysis of the SURMOUNT‐J trial.
Koutaro Yokote, Yasushi Fukushima, Tomotaka Shingaki, Tomonori Oura, Wataru Ogawa   +4 more
wiley   +1 more source

Drug repurposing: Dipeptidyl peptidase IV (DPP4) inhibitors as potential agents to treat SARS-CoV-2 (2019-nCov) infection [PDF]

, 2020
Praveen P. N. Rao, Amy Trinh Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, Ahmed A. Hefny   +6 more
openalex   +1 more source

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

Vascular Health and Risk Management, 2007
Baptist GallwitzDept. Medicine IV, Eberhard Karls University, Tuebingen, GermanyAbstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 ...
Baptist Gallwitz
doaj  

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1420-1430, February 2026.
Abstract Aims To assess whether periconceptional exposure to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with adverse outcomes in women with pregestational type 2 diabetes. Materials and Methods We linked Taiwan's Birth Certificate Application and National Health Insurance claims (2013–2022) to assemble a nationwide cohort of ...
Yi‐Chang Chou, Shih‐Han Weng, Feng‐Shiang Cheng, Chih‐Hao Tseng, Hsiao‐Yun Hu, Chieh‐Hsing Liu   +5 more
wiley   +1 more source

Meat Proteins as Dipeptidyl Peptidase IV Inhibitors and Glucose Uptake Stimulating Peptides for the Management of a Type 2 Diabetes Mellitus In Silico Study. [PDF]

Nutrients, 2019
Kęska P, Stadnik J, Bąk O, Borowski P.
europepmc   +1 more source

Quercetin and Coumarin Inhibit Dipeptidyl Peptidase-IV and Exhibits Antioxidant Properties: In Silico, In Vitro, Ex Vivo [PDF]

, 2020
Anand-Krishna Singh, Pankaj Kumar Patel, Komal Choudhary, Jaya Joshi, Dhananjay Yadav, Jun‐O Jin   +5 more
openalex   +1 more source